

spleen, kidney, liver, small intestine, placenta, lung or lymph nodes. A 2kb transcript was only observed in bone marrow and fetal liver. A signal was inconsistently observed with peripheral blood cells, probably due to platelet RNA contamination in some samples. Indeed, transcripts for platelet glycoprotein IIb (GPIIb), a platelet specific protein, were also detected in these positive samples.

On page 52, please replace the table beginning at line 4 with the following paragraph:

TABLE 1: Summary of TANGO 268 Sequence Information

Gene	cDNA	ORF	Figure	Accession Number
Human TANGO 268	SEQ ID NO:1	SEQ ID NO:2	Figure 1A-1B	207180
Mouse TANGO 268	SEQ ID NO:14	SEQ ID NO:15	Figure 6	PTA-225

**IN THE CLAIMS:**

Please amend the claims, as follows:

Cancel claims 30-32 and 48-52 without prejudice.

Amend claims 24-27, 29, 33, 34, 55, 56 and 65 to read as follows:

24. (Amended) A composition comprising a substantially purified antibody or fragment thereof that specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

25. (Amended) The composition of claim 24, wherein the antibody is a human antibody.

26. (Amended) A substantially purified non-human antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

27. (Amended) A substantially purified non-human monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

29. (Amended) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

33. (Amended) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, which antibody is conjugated to a therapeutic moiety.

34. (Amended) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, which antibody is linked to a detectable substance.

55. (Amended) A pharmaceutical composition comprising the composition of claim 24, 83, 84, 85 or 86, and a pharmaceutically acceptable carrier.

56. (Amended) A pharmaceutical composition comprising the composition of claim 24, 83, 84, 85 or 86, a therapeutic moiety, and a pharmaceutically acceptable carrier.

65. (Amended) A method of making an antibody that specifically recognizes GPVI, the method comprising:

- a) immunizing a mammal with a polypeptide comprising the amino acid sequence of SEQ ID NO:3, the amino acid sequence encoded by the cDNA

insert of the plasmid deposited with ATCC as Accession Number 207180; and

b) collecting a sample from the mammal that contains an antibody that specifically recognizes GPVI.

Add new claims 71-90, as follows:

71. (New) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180, wherein the antibody is a human, humanized or chimeric antibody.

72. (New) The antibody of claim 71 which is conjugated to a therapeutic moiety.

73. (New) The antibody of claim 71 which is linked to a detectable substance.

74. (New) The antibody of claim 73, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

75. (New) A kit comprising an antibody or fragment thereof as in claim 26, 87, 88, 89 or 90, and instructions for use.

76. (New) A kit comprising an antibody or fragment thereof as in claim 27, and instructions for use.

77. (New) A kit comprising an antibody or fragment thereof as in claim 29, and instructions for use.

78. (New) A kit comprising an antibody or fragment thereof as in claim 71, and instructions for use.

79. (New) A kit comprising an antibody or fragment thereof as in claim 73, and instructions for use.

80. (New) A pharmaceutical composition comprising an antibody or fragment thereof as in claim 26, 87, 88, 89 or 90, and a pharmaceutical carrier.

81. (New) A pharmaceutical composition comprising an antibody or fragment thereof as in claim 71, and a pharmaceutical carrier.

82. (New) A pharmaceutical composition comprising an antibody or fragment thereof as in claim 72, and a pharmaceutical carrier.

83. (New) The composition of claim 24, wherein said antibody represents at least 80% of total antibodies in the composition.

84. (New) The composition of claim 83, wherein said antibody represents at least 90% of total antibodies in the composition.

85. (New) The composition of claim 84, wherein said antibody represents at least 95% of total antibodies in the composition.

86. (New) The composition of claim 85, wherein said antibody represents at least 99% of total antibodies in the composition.

87. (New) The substantially purified non-human antibody of claim 26, wherein said antibody is at least 80% pure.

88. (New) The substantially purified non-human antibody of claim 87, wherein said antibody is at least 90% pure.